Mylan (MYL) Shares Sold by Boston Partners

Boston Partners decreased its position in Mylan (NASDAQ:MYL) by 29.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 100,950 shares of the company’s stock after selling 41,519 shares during the period. Boston Partners’ holdings in Mylan were worth $4,156,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Mylan by 34.6% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 128,117 shares of the company’s stock valued at $5,275,000 after purchasing an additional 32,965 shares during the last quarter. Zeke Capital Advisors LLC lifted its stake in Mylan by 20.0% in the first quarter. Zeke Capital Advisors LLC now owns 17,538 shares of the company’s stock valued at $722,000 after purchasing an additional 2,921 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its stake in Mylan by 120.8% in the first quarter. DekaBank Deutsche Girozentrale now owns 921,829 shares of the company’s stock valued at $37,423,000 after purchasing an additional 504,328 shares during the last quarter. SG Americas Securities LLC lifted its stake in Mylan by 123.7% in the first quarter. SG Americas Securities LLC now owns 61,275 shares of the company’s stock valued at $2,523,000 after purchasing an additional 33,889 shares during the last quarter. Finally, New York State Teachers Retirement System lifted its stake in Mylan by 1.0% in the first quarter. New York State Teachers Retirement System now owns 769,489 shares of the company’s stock valued at $31,680,000 after purchasing an additional 7,967 shares during the last quarter. Institutional investors and hedge funds own 83.53% of the company’s stock.

Several research firms recently commented on MYL. Deutsche Bank set a $50.00 price objective on Mylan and gave the company a “buy” rating in a research note on Wednesday, January 24th. Wells Fargo set a $43.00 price objective on Mylan and gave the company a “hold” rating in a research note on Thursday, January 18th. Susquehanna Bancshares reiterated a “positive” rating and issued a $55.00 price objective (up previously from $47.00) on shares of Mylan in a research note on Thursday, January 25th. BidaskClub downgraded Mylan from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 26th. Finally, Mizuho increased their target price on Mylan from $45.00 to $51.00 and gave the stock a “buy” rating in a research report on Thursday, March 15th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have issued a buy rating to the company. Mylan presently has a consensus rating of “Buy” and an average price target of $47.02.

In other news, insider Anthony Mauro sold 12,257 shares of the company’s stock in a transaction on Friday, March 2nd. The shares were sold at an average price of $40.35, for a total value of $494,569.95. Following the transaction, the insider now owns 147,435 shares of the company’s stock, valued at $5,949,002.25. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Paul Campbell sold 7,030 shares of the company’s stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $44.01, for a total transaction of $309,390.30. Following the completion of the transaction, the insider now directly owns 17,054 shares in the company, valued at approximately $750,546.54. The disclosure for this sale can be found here. In the last ninety days, insiders sold 269,287 shares of company stock worth $11,034,960. Insiders own 0.69% of the company’s stock.

Mylan stock opened at $40.08 on Friday. The firm has a market capitalization of $19.84 billion, a PE ratio of 8.79, a PEG ratio of 1.25 and a beta of 1.35. Mylan has a fifty-two week low of $38.30 and a fifty-two week high of $39.07. The company has a current ratio of 1.06, a quick ratio of 0.65 and a debt-to-equity ratio of 1.03.

Mylan (NASDAQ:MYL) last released its quarterly earnings results on Wednesday, May 9th. The company reported $0.96 earnings per share for the quarter, missing the consensus estimate of $0.99 by ($0.03). The firm had revenue of $2.68 billion during the quarter, compared to the consensus estimate of $2.74 billion. Mylan had a return on equity of 18.56% and a net margin of 6.04%. The company’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.93 EPS. sell-side analysts anticipate that Mylan will post 5.36 earnings per share for the current year.

About Mylan

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.

Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan (NASDAQ:MYL).

Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply